What is NCNA doing to address delisting

NuCana is taking several strategic steps to address the delisting threat and strengthen its market position: 1. **Reverse Stock Split**: NuCana has announced a 1:200 reverse stock split, which is set to take effect on August 8, 2025. This move is aimed at supporting liquidity and helping the company meet Nasdaq's minimum bid price requirement. 2. **Cancellation of Series A Warrants**: The company has successfully canceled all remaining Series A Warrants. This action, which involved a payment of $3.6 million, eliminates the overhanging rights from a previous direct offering and streamlines the company's capital structure. 3. **At-the-Market Sales Agreement**: NuCana has entered into a $100 million at-the-market sales agreement with A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd. This agreement will allow the company to offer and sell ADSs as needed, providing a potential source of capital. 4. **Direct Offering**: The company has priced a direct offering expected to raise approximately $7 million, with proceeds intended to advance drug discovery and development programs. 5. **Hearing Request**: NuCana plans to request a hearing to prevent suspension or delisting, which will temporarily halt any such actions. These actions are part of NuCana's broader strategy to address the delisting threat and improve its financial stability. The company's stock has seen a significant surge recently, which may be indicative of investor confidence in NuCana's ability to turn things around.